Cancer Research Technology
Log in Register
Menu

RAP as an LRP1 antagonist

Invented by Dudley K. Strickland
Invented at University Of Maryland

Info

Catalogue Number 153996
Antigen/Gene or Protein Targets lipoprotein receptor-related protein 1
Synonyms receptor-associated protein
Relevance LRP1 is an endocytic receptor that interacts with several ligands including alpha 2-macroglobulin. Functionally, the receptor mediates cellular signalling with implications in Alzheimer's disease. This receptor is expressed in brain, liver, and lung and localized to the cytoplasm and nucleus. Expression of LRP1 requires RAP, a molecular chaperone of LRP1.
In vivo applications inhibition of LRP1 function
In vitro applications inhibition of LRP1 function
Research Area Epigenetics & Nuclear Signalling, Cell Signaling & Signal Transduction, Neurobiology
Notes This RAP molecule was engineered to resist pH and heat-induced denaturation via the addition of a disulfide bond within the D3 domain and elimination of key histidine residues. This stable RAP molecule does not disassociate from LRP1 under acidic conditions and thus functions as a potent LRP1 antagonist both in-vitro and in-vivo.

References

There are 2 reference entries for this reagent.

View All References

References: 2 entries

Prasad et al. 2015. J Biol Chem. 290(28):17262-8. PMID: 26013822.

Generation of a Potent Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Antagonist by Engineering a Stable Form of the Receptor-associated Protein (RAP) D3 Domain.

Europe PMC ID: 26013822


Add a reference

References: 2 entries

Prasad et al. 2015. J Biol Chem. 290(28):17262-8. PMID: 26013822.

Generation of a Potent Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Antagonist by Engineering a Stable Form of the Receptor-associated Protein (RAP) D3 Domain.


Add a reference

Inventor Information